171 related articles for article (PubMed ID: 26080696)
41. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine.
Mishra D; Jain N; Rajoriya V; Jain AK
J Pharm Pharmacol; 2014 Aug; 66(8):1082-93. PubMed ID: 24641311
[TBL] [Abstract][Full Text] [Related]
42. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles.
Zhang X; Zhang H; Wu Z; Wang Z; Niu H; Li C
Eur J Pharm Biopharm; 2008 Mar; 68(3):526-34. PubMed ID: 17881202
[TBL] [Abstract][Full Text] [Related]
43. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification.
Zhang S; Tang C; Yin C
Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373
[TBL] [Abstract][Full Text] [Related]
44. Brain drug delivery of small molecules using immunoliposomes.
Huwyler J; Wu D; Pardridge WM
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14164-9. PubMed ID: 8943078
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
46. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
47. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
[TBL] [Abstract][Full Text] [Related]
48. [Research on Tat peptide-polyethylene glycol modified gelatin-siloxane nanoparticles across the blood-brain barrier].
Tian X; Wei F; Lin X; Feng W; Wang P
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):486-90, 500. PubMed ID: 22826945
[TBL] [Abstract][Full Text] [Related]
49. Hyaluronidase enzyme core-5-fluorouracil-loaded chitosan-PEG-gelatin polymer nanocomposites as targeted and controlled drug delivery vehicles.
Rajan M; Raj V; Al-Arfaj AA; Murugan AM
Int J Pharm; 2013 Sep; 453(2):514-22. PubMed ID: 23796828
[TBL] [Abstract][Full Text] [Related]
50. Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents.
Tosi G; Ruozi B; Belletti D; Vilella A; Zoli M; Vandelli MA; Forni F
Nanomedicine (Lond); 2013 Sep; 8(9):1373-83. PubMed ID: 23565661
[TBL] [Abstract][Full Text] [Related]
51. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
Lin A; Liu Y; Huang Y; Sun J; Wu Z; Zhang X; Ping Q
Int J Pharm; 2008 Jul; 359(1-2):247-53. PubMed ID: 18457928
[TBL] [Abstract][Full Text] [Related]
52. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.
Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB
Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883
[TBL] [Abstract][Full Text] [Related]
53. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
54. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
55. Central nervous system delivery of molecules across the blood-brain barrier.
Gosselet F; Loiola RA; Roig A; Rosell A; Culot M
Neurochem Int; 2021 Mar; 144():104952. PubMed ID: 33400964
[TBL] [Abstract][Full Text] [Related]
56. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.
Huang S; Li J; Han L; Liu S; Ma H; Huang R; Jiang C
Biomaterials; 2011 Oct; 32(28):6832-8. PubMed ID: 21700333
[TBL] [Abstract][Full Text] [Related]
57. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.
Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y
J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424
[TBL] [Abstract][Full Text] [Related]
58. Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery.
Gupta M; Chashoo G; Sharma PR; Saxena AK; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2014 Mar; 11(3):697-715. PubMed ID: 24512060
[TBL] [Abstract][Full Text] [Related]
59. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
60. Preparation and optimization of PMAA-chitosan-PEG nanoparticles for oral drug delivery.
Pawar H; Douroumis D; Boateng JS
Colloids Surf B Biointerfaces; 2012 Feb; 90():102-8. PubMed ID: 22037474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
